FocalTherics (NASDAQ:FOCL) Director Fran Schulz Purchases 10,000 Shares

FocalTherics (NASDAQ:FOCL) Director Fran Schulz bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director directly owned 15,100 shares of the company’s stock, valued at $71,725. The trade was a 196.08% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

FocalTherics Stock Performance

NASDAQ:FOCL opened at $4.76 on Monday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The company has a market cap of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The stock has a 50 day moving average of $5.39.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The company had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. Research analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Institutional Trading of FocalTherics

Institutional investors and hedge funds have recently modified their holdings of the company. Leonteq Securities AG purchased a new position in shares of FocalTherics during the 4th quarter valued at $313,000. Kovack Advisors Inc. purchased a new stake in FocalTherics in the 4th quarter worth $53,000. Rock Springs Capital Management LP increased its stake in FocalTherics by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after buying an additional 16,500 shares in the last quarter. Flax Pond Capital LLC bought a new stake in FocalTherics during the fourth quarter valued at about $2,623,000. Finally, SmartHarvest Portfolios LLC bought a new stake in FocalTherics during the first quarter valued at about $38,000. 62.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Mizuho set a $15.00 target price on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research report on Friday. Finally, Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.